Cargando…
Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose. Following administration, dabigatran plasma level rebounds have been reported but its consequ...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897981/ https://www.ncbi.nlm.nih.gov/pubmed/33665315 http://dx.doi.org/10.1016/j.tcr.2021.100422 |